295 related articles for article (PubMed ID: 31127190)
1. Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer.
Kretschmer A; Zhang F; Somasekharan SP; Tse C; Leachman L; Gleave A; Li B; Asmaro I; Huang T; Kotula L; Sorensen PH; Gleave ME
Sci Rep; 2019 May; 9(1):7826. PubMed ID: 31127190
[TBL] [Abstract][Full Text] [Related]
2. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
[TBL] [Abstract][Full Text] [Related]
3. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
4. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
5. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.
Yang L; Xie S; Jamaluddin MS; Altuwaijri S; Ni J; Kim E; Chen YT; Hu YC; Wang L; Chuang KH; Wu CT; Chang C
J Biol Chem; 2005 Sep; 280(39):33558-65. PubMed ID: 16061480
[TBL] [Abstract][Full Text] [Related]
6. Macrophages enhance 3D invasion in a breast cancer cell line by induction of tumor cell tunneling nanotubes.
Carter KP; Hanna S; Genna A; Lewis D; Segall JE; Cox D
Cancer Rep (Hoboken); 2019 Dec; 2(6):e1213. PubMed ID: 32467880
[TBL] [Abstract][Full Text] [Related]
7. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
[TBL] [Abstract][Full Text] [Related]
8. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
9. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
10. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
Liu Z; Zhu G; Getzenberg RH; Veltri RW
J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
[TBL] [Abstract][Full Text] [Related]
11. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
12. Tunneling-nanotube development in astrocytes depends on p53 activation.
Wang Y; Cui J; Sun X; Zhang Y
Cell Death Differ; 2011 Apr; 18(4):732-42. PubMed ID: 21113142
[TBL] [Abstract][Full Text] [Related]
13. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
14. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
15. Differential identity of Filopodia and Tunneling Nanotubes revealed by the opposite functions of actin regulatory complexes.
Delage E; Cervantes DC; Pénard E; Schmitt C; Syan S; Disanza A; Scita G; Zurzolo C
Sci Rep; 2016 Dec; 6():39632. PubMed ID: 28008977
[TBL] [Abstract][Full Text] [Related]
16. Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
Lee TJ; Sartor O; Luftig RB; Koochekpour S
Mol Cancer; 2004 Nov; 3():31. PubMed ID: 15548330
[TBL] [Abstract][Full Text] [Related]
17. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers.
Lin HK; Hu YC; Yang L; Altuwaijri S; Chen YT; Kang HY; Chang C
J Biol Chem; 2003 Dec; 278(51):50902-7. PubMed ID: 14555644
[TBL] [Abstract][Full Text] [Related]
18. [Connection of intracellular protein YB-1 localization in cell cultures of human tumors with multidrug resistance].
Rybalkina EIu; Stromskaia TP; Ovchinnikov LP; Stavrovskaia AA
Vopr Onkol; 2013; 59(5):623-8. PubMed ID: 24260892
[TBL] [Abstract][Full Text] [Related]
19. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
20. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
